Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Real-life treatment of patients with cholinergic urticaria in Germanspeaking countries
Filename | 367. Mellerowicz et al., engl, Real-life treatment chol. urt., JDDG 2019.pdf |
Filesize | 391.36 KB |
Version | o.367 |
Date added | June 5, 2019 |
Downloaded | 4 times |
Category | Original Work |
Tags | cholinergic urticaria |
Authors | Mellerowicz, E., Weller, K., Zuberbier, T., Maurer, M., and Altrichter, S. |
Citation | Mellerowicz, E., Weller, K., Zuberbier, T., Maurer, M., and Altrichter, S.: Real life treatment of patients with cholinergic urticaria in German speaking countries. J. Dtsch. Dermatol. Ges. 2019: 17; 1141-1147. |
Corresponding authors | Maurer, M. |
DocNum | o.367 |
DocType | |
Edition; Page | 17; 1141-1147 |
IF | 3.66 |
Publisher | J. Dtsch. Dermatol. Ges. |
ReleaseDate | 2019 |
Background: Cholinergic urticaria (CholU) is a frequent type of chronic inducible urticaria. Symptomatic treatment with second-generation antihistamines (sgAH) is recommended by current guidelines as first-line therapy, but little is known about how patients with CholU are treated in real life and how they respond to treatment.
Aim: To assess real-life treatment of CholU in German-speaking countries.
Methods: Patients with CholU (n = 111) took part in an online survey study that assessed their treatments and their treatment responses.
Results: Virtually all patients (97 %) had used antihistamines, 87 % of them sgAH; 23 % had also taken first-generation antihistamines (fgAH). The proportion of patients who benefited from standard-dosed antihistamine treatment was low (sgAH: 32 % vs. fgAH: 16 %), and side effects of sgAH and fgAH were comparable. Updosing of antihistamines had been tried by 66 patients (59 %) (most commonly [98 %, n = 65] with sgAH) and resulted in marginally better responses (sgAH: 38 % vs. fgAH: 32 %). Only very few patients had used other treatments, mostly corticosteroids (30 %) and omalizumab (5 %).
Conclusions: SgAH were commonly used, but insufficient in about two thirds of CholU patients. Accordingly, improved use of third-line and fourth-line treatment options and development of better therapies for patients with CholU are needed.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.